サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：抗ウイルス剤併用療法市場：薬剤組み合わせ別、製品別、流通チャネル別、国別、地域別：産業分析、市場規模、市場シェア、2023-2030年予測
市場調査レポート
商品コード
1351389

抗ウイルス剤併用療法市場：薬剤組み合わせ別、製品別、流通チャネル別、国別、地域別：産業分析、市場規模、市場シェア、2023-2030年予測

Antiviral Combination Therapies Market, By Drug Combination, By Product, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030

出版日
ページ情報
英文 246 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
抗ウイルス剤併用療法市場：薬剤組み合わせ別、製品別、流通チャネル別、国別、地域別：産業分析、市場規模、市場シェア、2023-2030年予測
出版日: 2023年08月01日
発行: AnalystView Market Insights
ページ情報: 英文 246 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

レポートハイライト

抗ウイルス剤併用療法の市場規模は2022年に468億600万米ドルとなり、2023年から2030年にかけてCAGR 4.8%で拡大

抗ウイルス剤併用療法市場- 市場力学：

  • ウイルス感染症の拡大が市場成長を牽引
  • ウイルス感染症の蔓延が予測期間中の市場成長を牽引するとみられます。毎年、世界人口のかなりの割合が、HIV/AIDS、肝炎、COVID-19、インフルエンザ、ヘルペスなどのウイルス性疾患の影響を受けています。単剤療法と比較して、抗ウイルス薬の併用療法には、薬剤耐性の発現を先延ばしまたは抑制する能力が高いなど、いくつかの利点があります。さらに、抗ウイルス薬併用療法は、HCVやHIVを含む慢性ウイルス性疾患の治療におけるゴールドスタンダードとしての地位を確立しています。抗ウイルス剤併用療法は、薬剤耐性を低下させ、ウイルス感染を制限するための高活性抗レトロウイルス療法を利用することで、HIVの治療に不可欠なものとなっています。NCBIによれば、インフルエンザのような急性ウイルス感染症の効果的な治療に加えて、これらの併用薬は薬剤耐性を低下させ、ウイルスの繁殖を阻害し、効率を改善し、死亡率を低下させることができます。このため、市場成長の原動力になると期待されています。

抗ウイルス剤併用療法市場-セグメンテーション分析：

  • 抗ウイルス剤併用療法の世界市場は、薬剤の組み合わせ、製品、流通チャネル、地域に基づいてセグメント化されます。
  • 薬剤の組み合わせに基づき、世界の抗ウイルス剤併用療法市場はRTI/NNRTI、インテグラーゼ阻害剤/NRTI、NRTI、NRTI/プロテアーゼ阻害剤、その他に区分されます。予測期間中、RTI/NNRTIセグメントが市場を独占すると予想されます。RTI/NNRTIの集合体医薬品は、抗ウイルス剤の併用療法、特にHIV/AIDS治療の分野で重要な役割を担っており、その拡大が期待されます。これは、ウイルスの増殖に歯止めをかけるのに役立ちます。さらに、RTIのサブグループであるNRTIは、ヌクレオシドアナログであり、ウイルスDNA鎖に見られる天然のヌクレオチドを模倣し、ウイルスDNAの産生を停止させることを主な目的としています。
  • 抗ウイルス剤併用療法市場-地理的洞察
  • 地理的には、この市場は北米、ラテンアメリカ、欧州、アジア太平洋、中東・アフリカの各地域に広がっています。これらの地域は、ビジネスを展開する国によってさらに分けられます。北米は、HIV、肝炎、インフルエンザなどの有病率の増加により、予測期間中に市場を独占すると予想されます。さらに、北米での市場拡大は、重要な製薬企業の存在や継続的な研究開発プロジェクトによっても大きく後押しされると思われます。一方、アジア太平洋地域は予測期間中に最も高いCAGRで成長すると予想されます。同地域の市場成長は、製薬業界の成長と政府のイニシアチブの増加に起因しています。

抗ウイルス剤併用療法市場-競合情勢：

市場で事業を展開する主要企業は以下の通り：Merck &Co.Inc.、ViiVヘルスケア、Gilead Sciences Inc.、AbbVie Inc.、Janssen Pharmaceuticals、Bristol Myers Squibb、Boehringer Ingelheim Pharmaceuticals Inc.、Roche Holding AG、Mylan N.V.、Cipla Ltd.などです。

目次

第1章 抗ウイルス併用療法市場概要

  • 調査範囲
  • 市場推定年数

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 抗ウイルス併用療法の主要な市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 今後の市場動向

第4章 抗ウイルス併用療法産業調査

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しのマッピング
  • 規制枠組みの分析

第5章 抗ウイルス併用療法市場：COVID-19症の影響分析

  • 新型コロナウイルス感染症以前の影響分析
  • 新型コロナウイルス感染症後の影響分析

第6章 抗ウイルス併用療法の市場情勢

  • 抗ウイルス併用療法の市場シェア分析、2022年
  • 主要メーカー別の内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 抗ウイルス併用療法市場- 薬剤の組み合わせ別

  • 概要
    • 医薬品の組み合わせ別のセグメントシェア分析
    • RTI/NNRTI
    • インテグラーゼ阻害剤/NRTI
    • NRTI
    • NRTI/プロテアーゼ阻害剤
    • その他

第8章 抗ウイルス併用療法市場- 製品別

  • 概要
    • 製品別セグメントシェア分析
    • ブランド
    • ジェネリック

第9章 抗ウイルス併用療法市場- 流通チャネル別

  • 概要
    • 販売チャネル別のセグメントシェア分析
    • 病院薬局
    • 小売薬局
    • その他

第10章 抗ウイルス併用療法市場-地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東とアフリカ
    • 概要
    • 中東およびアフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析- 抗ウイルス薬併用療法業界

  • 競合ダッシュボード
  • 企業プロファイル
    • Merck &Co. Inc.
    • ViiV Healthcare
    • Gilead Sciences Inc.
    • AbbVie Inc.
    • Janssen Pharmaceuticals
    • Bristol Myers Squibb
    • Boehringer Ingelheim Pharmaceuticals Inc.
    • Roche Holding AG
    • Mylan NV
    • Cipla Ltd.

第12章 アナリストの全方位展望

図表

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Antiviral Combination Therapies Market: Drug Combination Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Combination
  • TABLE Global Antiviral Combination Therapies Market, by Drug Combination 2018-2030 (USD Million)
  • TABLE Antiviral Combination Therapies Market: Product Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Product
  • TABLE Global Antiviral Combination Therapies Market, by Product 2018-2030 (USD Million)
  • TABLE Antiviral Combination Therapies Market: Distribution Channel Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
  • TABLE Global Antiviral Combination Therapies Market, by Distribution Channel 2018-2030 (USD Million)
  • TABLE Antiviral Combination Therapies Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Antiviral Combination Therapies Market, by Region 2018-2030 (USD Million)
  • TABLE North America Antiviral Combination Therapies Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Antiviral Combination Therapies Market, by Drug Combination, 2018-2030 (USD Million)
  • TABLE North America Antiviral Combination Therapies Market, by Product, 2018-2030 (USD Million)
  • TABLE North America Antiviral Combination Therapies Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Europe Antiviral Combination Therapies Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Antiviral Combination Therapies Market, by Drug Combination, 2018-2030 (USD Million)
  • TABLE Europe Antiviral Combination Therapies Market, by Product, 2018-2030 (USD Million)
  • TABLE Europe Antiviral Combination Therapies Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Asia Pacific Antiviral Combination Therapies Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Antiviral Combination Therapies Market, by Drug Combination, 2018-2030 (USD Million)
  • TABLE Asia Pacific Antiviral Combination Therapies Market, by Product, 2018-2030 (USD Million)
  • TABLE Asia Pacific Antiviral Combination Therapies Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Latin America Antiviral Combination Therapies Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Antiviral Combination Therapies Market, by Drug Combination, 2018-2030 (USD Million)
  • TABLE Latin America Antiviral Combination Therapies Market, by Product, 2018-2030 (USD Million)
  • TABLE Latin America Antiviral Combination Therapies Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Antiviral Combination Therapies Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Antiviral Combination Therapies Market, by Drug Combination, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Antiviral Combination Therapies Market, by Product, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Antiviral Combination Therapies Market, by Distribution Channel, 2018-2030 (USD Million)
目次
Product Code: ANV1684

REPORT HIGHLIGHT

Antiviral Combination Therapies Market size was valued at USD 46,806 Million in 2022, expanding at a CAGR of 4.8% from 2023 to 2030.

Antiviral combination treatments, sometimes referred to as aggregate antiviral therapy (CART), include using several antiviral medications together to treat viral infections. This method includes combining various antiviral drugs that target various viral replication cycle components or individual viral traces to increase treatment efficacy and lower the risk of drug resistance. Antiviral aggregate treatment is necessary because viruses frequently have rapid mutation rates, which enable them to quickly adapt and build up resistance to single capsules.

Antiviral Combination Therapies Market - Market Dynamics:

  • The growing prevalence of viral infection drives the market growth
  • The growing prevalence of viral infection is expected to drive market growth during the forecast period. Each year, a sizable fraction of the world's population is impacted by viral illnesses including HIV/AIDS, hepatitis, COVID-19, influenza, and herpes. Compared to single-drug therapy, antiviral combination medicines have several advantages, including a greater ability to postpone or inhibit the development of drug resistance. Additionally, antiviral combination therapy has established itself as the gold standard for the treatment of chronic viral diseases including HCV and HIV. Antiviral combination medicines have been essential in the treatment of HIV by utilizing highly active antiretroviral therapy for lowering drug resistance and limiting virus transmission. In addition to effectively treating acute viral infections like influenza, these combination medicines, according to NCBI, can also lower drug resistance, inhibit viral reproduction, improve efficiency, and lower the mortality rate. Thus, this is expected to drive the market growth.

Antiviral Combination Therapies Market - Key Insights:

  • As per the analysis shared by our research analyst, the global Antiviral Combination Therapies market is estimated to grow annually at a CAGR of around 4.8% over the forecast period (2023-2030)
  • The antiviral Combination Therapies industry is projected to grow at a significant rate owing to the growing prevalence of viral infection.
  • Based on the drug combination, the RTI/NNRTI segment is expected to dominate the market during the forecast period.
  • Based on region, North America is expected to dominate the market over the forecast period.

Antiviral Combination Therapies Market- Segmentation Analysis:

  • The Global Antiviral Combination Therapies Market is segmented based on Drug Combination, Product, Distribution Channel and Region.
  • Based on the drug combination, the global Antiviral Combination Therapies market is segmented into RTI/NNRTI, Integrase Inhibitor/NRTI, NRTI, NRTI/Protease Inhibitor, and Others. The RTI/NNRTI segment is expected to dominate the market during the forecast period. RTI/NNRTI aggregate medicines, which are significant in the field of antiviral combination treatments, notably in the treatment of HIV/AIDS, can be credited with the expansion. It aids in putting a stop to viral proliferation. Additionally, NRTIs, a subgroup of RTIs, are nucleoside analogs that imitate the natural nucleotides found in the viral DNA chain with the primary goal of stopping viral DNA production.

Antiviral Combination Therapies Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the market over the forecast period due to the increasing prevalence of HIV, Hepatitis, Influenza and others. Moreover, the market's expansion in North America will also be significantly aided by the presence of important pharmaceutical businesses as well as continuing research and development projects. On the other hand, the Asia Pacific is expected to grow at the highest CAGR during the forecast period. The market growth in the region is attributed to the growing pharmaceutical industry and increasing government initiatives.

Antiviral Combination Therapies Market- Competitive Landscape:

The key players operating in the market are: Merck & Co. Inc., ViiV Healthcare, Gilead Sciences Inc., AbbVie Inc., Janssen Pharmaceuticals, Bristol Myers Squibb, Boehringer Ingelheim Pharmaceuticals Inc., Roche Holding AG, Mylan N.V. and Cipla Ltd.

Recent Developments:

In February 2023, Atea Pharmaceuticals unveiled impressive findings from a Phase 2 clinical study of AT-527, a COVID-19 capacity treatment. A small chemical called AT-527 interferes with the SARS-CoV-2 virus's entrance mechanism. This breakthrough may improve the commercial environment for antiviral combo treatments.

Key features of the study:

  • This proposed research study on Antiviral Combination Therapies market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year
  • The report provides the client the latest up-to-date and trending insights about the Antiviral Combination Therapies market.
  • The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Antiviral Combination Therapies market
  • The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Antiviral Combination Therapies market
  • Impact of COVID-19 on Antiviral Combination Therapies market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Antiviral Combination Therapies market post-COVID will also be covered.
  • In order to give the users of this report a comprehensive view on the Antiviral Combination Therapies market, we have also included competitive landscape and key innovator analysis for the Antiviral Combination Therapies market.
  • The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
  • The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Antiviral Combination Therapies market.
  • In addition, the report also unveils the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.
  • The global Antiviral Combination Therapies market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ANTIVIRAL COMBINATION THERAPIES MARKET KEY PLAYERS

  • Merck & Co. Inc.
  • ViiV Healthcare
  • Gilead Sciences Inc.
  • AbbVie Inc.
  • Janssen Pharmaceuticals
  • Bristol Myers Squibb
  • Boehringer Ingelheim Pharmaceuticals Inc.
  • Roche Holding AG
  • Mylan N.V.
  • Cipla Ltd.

GLOBAL ANTIVIRAL COMBINATION THERAPIES MARKET, BY DRUG COMBINATION

  • RTI/NNRTI
  • Integrase Inhibitor/NRTI
  • NRTI
  • NRTI/Protease Inhibitor
  • Others

GLOBAL ANTIVIRAL COMBINATION THERAPIES MARKET, BY PRODUCT

  • Branded
  • Generic

GLOBAL ANTIVIRAL COMBINATION THERAPIES MARKET, BY DISTRIBUTION CHANNEL

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

GLOBAL ANTIVIRAL COMBINATION THERAPIES MARKET, BY REGION

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
    • Russia
    • Netherlands
    • Sweden
    • Poland
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • South Korea
    • Japan
    • Australia
    • Thailand
    • Indonesia
    • Philippines
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
    • Rest of LATAM
  • The Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Turkey
    • Algeria
    • Egypt
    • Rest of MEA

Table of Contents

1. Antiviral Combination Therapies Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Antiviral Combination Therapies Market Snippet by Drug Combination
    • 2.1.2. Antiviral Combination Therapies Market Snippet by Product
    • 2.1.3. Antiviral Combination Therapies Market Snippet by Distribution Channel
    • 2.1.4. Antiviral Combination Therapies Market Snippet by Country
    • 2.1.5. Antiviral Combination Therapies Market Snippet by Region
  • 2.2. Competitive Insights

3. Antiviral Combination Therapies Key Market Trends

  • 3.1. Antiviral Combination Therapies Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Antiviral Combination Therapies Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Antiviral Combination Therapies Market Opportunities
  • 3.4. Antiviral Combination Therapies Market Future Trends

4. Antiviral Combination Therapies Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Antiviral Combination Therapies Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Antiviral Combination Therapies Market Landscape

  • 6.1. Antiviral Combination Therapies Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Antiviral Combination Therapies Market - By Drug Combination

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Combination, 2022 & 2030 (%)
    • 7.1.2. RTI/NNRTI
    • 7.1.3. Integrase Inhibitor/NRTI
    • 7.1.4. NRTI
    • 7.1.5. NRTI/Protease Inhibitor
    • 7.1.6. Others

8. Antiviral Combination Therapies Market - By Product

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Product, 2022 & 2030 (%)
    • 8.1.2. Branded
    • 8.1.3. Generic

9. Antiviral Combination Therapies Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2022 & 2030 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Others

10. Antiviral Combination Therapies Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Antiviral Combination Therapies Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Antiviral Combination Therapies Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Antiviral Combination Therapies Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Antiviral Combination Therapies Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Antiviral Combination Therapies Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Antiviral Combination Therapies Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Merck & Co. Inc.
    • 11.2.2. ViiV Healthcare
    • 11.2.3. Gilead Sciences Inc.
    • 11.2.4. AbbVie Inc.
    • 11.2.5. Janssen Pharmaceuticals
    • 11.2.6. Bristol Myers Squibb
    • 11.2.7. Boehringer Ingelheim Pharmaceuticals Inc.
    • 11.2.8. Roche Holding AG
    • 11.2.9. Mylan N.V.
    • 11.2.10. Cipla Ltd.

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us